Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Evoke Pharma (EVOK) Income from Continuing Operations (2020 - 2025)

Historic Income from Continuing Operations for Evoke Pharma (EVOK) over the last 6 years, with Q3 2025 value amounting to -$1.2 million.

  • Evoke Pharma's Income from Continuing Operations rose 1190.06% to -$1.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$5.2 million, marking a year-over-year increase of 1497.85%. This contributed to the annual value of -$5.4 million for FY2024, which is 3131.43% up from last year.
  • According to the latest figures from Q3 2025, Evoke Pharma's Income from Continuing Operations is -$1.2 million, which was up 1190.06% from -$1.6 million recorded in Q2 2025.
  • Evoke Pharma's Income from Continuing Operations' 5-year high stood at -$1.2 million during Q3 2025, with a 5-year trough of -$2.7 million in Q1 2021.
  • Its 5-year average for Income from Continuing Operations is -$1.8 million, with a median of -$1.8 million in 2022.
  • In the last 5 years, Evoke Pharma's Income from Continuing Operations skyrocketed by 6712.34% in 2021 and then tumbled by 2397.05% in 2025.
  • Over the past 5 years, Evoke Pharma's Income from Continuing Operations (Quarter) stood at -$1.7 million in 2021, then fell by 7.82% to -$1.8 million in 2022, then dropped by 10.21% to -$2.0 million in 2023, then skyrocketed by 39.98% to -$1.2 million in 2024, then increased by 3.06% to -$1.2 million in 2025.
  • Its Income from Continuing Operations stands at -$1.2 million for Q3 2025, versus -$1.6 million for Q2 2025 and -$1.3 million for Q1 2025.